B. Koidl et al., EFFECTS OF THE CLASS-III ANTIARRHYTHMIC DRUG AMBASILIDE ON OUTWARD CURRENTS IN HUMAN ATRIAL MYOCYTES, Naunyn-Schmiedeberg's archives of pharmacology, 353(2), 1996, pp. 226-232
We have studied the inhibitory influence of the class III antiarrhythm
ic drug ambasilide (LU 47110) on the transient outward current I-to1 a
nd the sustained current I-so following inactivation of I-to1, in huma
n atrial myocytes. The two currents are separated by a mathematical pr
ocedure based on the amplitudes and time constants of the biexponentia
l inactivation of the total outward current. The frequency dependence,
the recovery from inactivation and the kinetics of activation and ina
ctivation are described. Ambasilide reversibly and concentration depen
dently inhibited I-to1, I-so and the sodium current I-Na. Concentratio
n required for half maximal inhibition (IC50) for the effects on I-to1
and I-so were 23.3 mu mol/l and 45.7 mu mol/l respectively, concentra
tions shown by others to be effective in terminating and preventing fi
brillation in a dog atrial arrhythmia model. Ambasilide not only reduc
ed the amplitude of I-to1 and I-so but also accelerated the time cours
e of inactivation from 14.22 to 6.69 ms and from 202.3 to 87.9 ms resp
ectively. The amplitude of I-to1 showed only a small dependence on sti
mulation frequency characteristic for human atrial myocytes, whereas I
-so was reduced significantly at higher stimulation frequencies. Ambas
ilide did not change these relationships (0.1-4 Hz) and therefore did
not show the reverse use-dependence known from other class III antiarr
hythmic agents and which is an important property for a prospective an
tiarrhythmic drug. The lack of an effect of ambasilide on both steady-
state activation and inactivation of I-to1, and the time constant of r
ecovery from inactivation, suggests that ambasilide acts by changing c
onductance rather than by influencing the gating mechanism. The descri
bed characteristics make ambasilide an interesting substance in the gr
oup of class III antiarrhythmic drugs.